MA50864A - Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques - Google Patents

Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques

Info

Publication number
MA50864A
MA50864A MA050864A MA50864A MA50864A MA 50864 A MA50864 A MA 50864A MA 050864 A MA050864 A MA 050864A MA 50864 A MA50864 A MA 50864A MA 50864 A MA50864 A MA 50864A
Authority
MA
Morocco
Prior art keywords
acetylcystein
urea
treatment
formulation based
dermatological disorders
Prior art date
Application number
MA050864A
Other languages
English (en)
Inventor
Alessandro Calderan
Original Assignee
Alessandro Calderan
Dermalena Di Calderan Andrea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alessandro Calderan, Dermalena Di Calderan Andrea filed Critical Alessandro Calderan
Publication of MA50864A publication Critical patent/MA50864A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA050864A 2017-11-06 2018-10-29 Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques MA50864A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT201700125963 2017-11-06

Publications (1)

Publication Number Publication Date
MA50864A true MA50864A (fr) 2020-09-16

Family

ID=61527092

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050864A MA50864A (fr) 2017-11-06 2018-10-29 Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques

Country Status (5)

Country Link
US (1) US20210052524A1 (fr)
EP (1) EP3706714B1 (fr)
ES (1) ES2932359T3 (fr)
MA (1) MA50864A (fr)
WO (1) WO2019086366A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2100456A1 (hu) * 2021-12-28 2023-08-28 Semmelweis Egyetem Szemcsepp készítmény

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733535A (en) 1995-10-25 1998-03-31 The Procter & Gamble Co. Topical compositions containing N-acetylcysteine and odor masking materials
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
US20030229141A1 (en) 1999-01-08 2003-12-11 Yu Ruey J. N-acetyl cysteine and its topical use
US20030138466A1 (en) * 2001-11-28 2003-07-24 Bradley Pharmaceuticals, Inc. Antioxidant dermatological composition
EP1545210B1 (fr) * 2002-08-20 2007-01-24 Lonza, Inc. Compositions antimicrobiennes synergiques stables a faible teneur en formaldehyde libre de donneurs aldehyde et acide dehydroacetique
US7556819B1 (en) * 2003-07-25 2009-07-07 Opi Products, Inc. Skin composition
US20110044920A1 (en) * 2009-08-07 2011-02-24 Mary Kay Inc. Topical skin care formulations
EP2397125A1 (fr) 2010-06-15 2011-12-21 Histocell, S.L. Composition antioxydante
AU2013257830A1 (en) * 2012-05-11 2014-11-20 Cipla Limited Pharmaceutical composition
CN104225583B (zh) * 2014-09-03 2016-09-28 苏州瑞派尔生物科技有限公司 一种用于皮肤损伤修复的组合物
US20160338993A1 (en) 2015-05-21 2016-11-24 The Regents Of The University Of California Wound healing

Also Published As

Publication number Publication date
US20210052524A1 (en) 2021-02-25
EP3706714A1 (fr) 2020-09-16
ES2932359T3 (es) 2023-01-18
EP3706714B1 (fr) 2022-09-14
WO2019086366A1 (fr) 2019-05-09

Similar Documents

Publication Publication Date Title
MA50417A (fr) Procédés d&#39;utilisation d&#39;inhibiteurs de l&#39;ehmt2 dans le traitement ou la prévention de troubles du sang
MA50786A (fr) Produit d&#39;association pour le traitement de troubles neurologiques et/ou psychiatriques
MA46052A (fr) Modulateurs du récepteur hormonal pour le traitement d&#39;états et de troubles métaboliques
IL255203B (en) Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders
MA42819A (fr) Procédés pour le traitement d&#39;infections virales à arenaviridae et coronaviridae
MA49069A (fr) Procédés et compositions pour le traitement d&#39;apnée du sommeil
MA45798A (fr) Compositions et procédés d&#39;inhibition de masp-3 pour le traitement de maladies et troubles divers
MA50155A (fr) Acides aminés à chaîne ramifiée pour le traitement d&#39;une lésion neuronale
MA50849A (fr) Substances et procédés pour le traitement d&#39;hémoglobinopathies
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
DK3405215T3 (da) Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser
SG11202011296VA (en) Compositions and methods for the treatment of parkinson&#39;s disease
MA51056A (fr) Compositions et méthodes pour le traitement d&#39;affections métaboliques
MA55148A (fr) Composés d&#39;aryl-aniline et d&#39;hétéroaryl-aniline pour le traitement de marques de naissance
MA50233A (fr) Mic-1 et glp-1 destinés à être utilisés dans le traitement de l&#39;obésité
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
MA47074A (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d&#39;affections liées à l&#39;oxalate
MA43825A (fr) Schémas posologiques pour le traitement d&#39;infections fongiques
MA49524A (fr) Compositions d&#39;antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
IL269400A (en) Medicines and preparations for the treatment of eye disorders
MA45668A (fr) Schémas posologiques d&#39;antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
MA50864A (fr) Formulation à base de n-acétylcystéine et d&#39;urée pour le traitement de troubles dermatologiques
MA53636A (fr) Agent de traitement de troubles dermatologiques